Clinical Trial Update: Pharmacokinetics and Safety of RV521 Formulations [Phase 1]

View source ↗

Summary

Pfizer completed a Phase 1 pharmacokinetics and safety evaluation of RV521 formulations for Respiratory Syncytial Virus Infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• RV521

Snippet

Sponsor: Pfizer | Conditions: Respiratory Syncytial Virus Infections | Phase 1 | Status: COMPLETED